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OBJECTIVES: Previous economic studies ofHelicobacter py-
lori eradication in dyspepsia and peptic ulcer disease have
not measured quality of life using utilities (preference prob-
abilities), which are needed to compare the cost-effective-
ness of such treatment to other health care interventions.
The goals of this study were to measure quality of life in
patients with dyspepsia or peptic ulcer and apply these
measurements to published models of disease management
to determine cost-effectiveness in dollars per quality-ad-
justed life year (QALY) gained.
METHODS: Utilities for dyspepsia and peptic ulcer disease
were measured in adult patients (n5 73) on chronic acid
suppression for peptic ulcer or ulcer-like dyspepsia. Median
utility values were applied to the results of published cost-
effectiveness analyses and a previously validated dyspepsia
model. Cost-utility ratios for earlyH. pylori eradication in
uninvestigated dyspepsia and peptic ulcer disease were then
computed.
RESULTS: The total disutility, or lost quality of life, for an
ulcer was 0.11 QALY, of which 0.09 QALY was attributed
to dyspeptic symptoms. After these results were incorpo-
rated into published studies, cost-utility ratios for ulcer
treatment varied from $3,100 to $12,500 per QALY gained,
whereas estimates for uninvestigated dyspepsia manage-
ment ranged from $26,800 to $59,400 per QALY. Sensitiv-
ity analyses indicated a range of $1,300 to $27,300 per
QALY for management of duodenal ulcer and $15,000 to
$129,700 per QALY for dyspepsia.
CONCLUSIONS: Strategies that emphasize earlyH. pylori
radication were cost-effective for patients with peptic ulcer
and possibly cost-effective for patients with uninvestigated
dyspepsia, relative to other medical interventions. Dyspeptic
symptoms cause significant disutility that should be incor-
porated in future cost-effectiveness analyses of treatment
strategies. (Am J Gastroenterol 2001;96:338–347. © 2001
by Am. Coll. of Gastroenterology)
INTRODUCTION
The discovery of the role ofHelicobacter pylorihas greatly
altered the diagnosis and treatment of patients with dyspep-
sia and peptic ulcer disease. Several cost-effectiveness anal-
yses (1–23) have evaluated the cost and quality tradeoffs of
treating patients with these conditions by modeling the rate
of H. pylori eradication, disease recurrence, need for endos-
copy, and associated resource use. Cost-effectiveness in
these studies was expressed in terms such as dollars per
ulcer cured or prevented, cost per patient treated, or per-
centage of time free from ulcer symptoms. As health ben-
efits in these studies were reported in terms of ulcer disease
only, it was not possible to compare the cost-effectiveness
of H. pylori eradication with the treatment of other medical
conditions.
The quality-adjusted life-year (QALY) is a standard mea-
sure of health benefit recommended by the national Panel on
Cost-Effectiveness in Health and Medicine (1996) (24–26).
Its incorporation into economic analyses of the treatment of
uninvestigated dyspepsia and peptic ulcer would enable
policymakers to judge the cost-effectiveness of such strat-
egies compared to other medical interventions. However,
better information is needed about patient preferences (util-
ities), which are used to calculate QALYs. The only pub-
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lished cost-effectiveness analysis to use utilities did not
measure them directly but estimated them from Index of
Well-Being scores, and the estimated ulcer disutility of
0.021 QALY did not account for lost utility due to dyspeptic
symptoms (6).
In this study, we interviewed patients with ulcer-like
dyspeptic symptoms to assess their preferences (utilities)
regarding ulcer-related health states and other outcomes
associated with the conditions. We then identified published
economic analyses of peptic ulcer disease and uninvesti-
gated dyspepsia, and used the empirically derived utilities to
calculate the cost-effectiveness of various management
strategies. We also updated our previous cost-effectiveness
model to reflect improved estimates ofH. pylori prevalence,
test performance, treatment efficacy, and clinical costs to




Patients were members of a large Northern California health
maintenance organization who were participating in the
STOMACH (Study of Management and Costs ofHelico-
bacter pyloriInfection) investigation of the care of patients
on long-term acid suppressive therapy. The Kaiser Founda-
tion Research Institute’s Review Board for the protection of
human subjects approved the study. Subjects were identified
through pharmacy record review. Patients who had re-
ceived H2-receptor antagonists or proton pump inhibitors
for at least three 30-day periods during the most recent 12
months and who had diagnoses of duodenal ulcer, gastric
ulcer, peptic ulcer disease, or gastritis (according to the
International Classification of Diseases, ninth revision,
codes) were contacted by mail. From the respondents to
this mailing, enrollees were selected if medical chart
review confirmed a physician diagnosis of peptic ulcer
disease documented by endoscopy or x-ray, or dyspeptic
symptoms defined as fasting or postprandial epigastric
pain relieved with antacid, food, H2-receptor antagonists,
or proton pump inhibitors.
Subjects with classic gastroesophageal reflux disease
symptoms (substernal burning and/or regurgitation, worse
after meals or when supine and relieved with acid suppres-
sive medications) were excluded unless they also had doc-
umented peptic ulcer disease or dyspeptic symptoms. Fur-
ther exclusion criteria were as follows: age,18 yr or.80
yr; upper GI tract malignancy; contraindication to endos-
copy; pregnancy; allergy to amoxicillin, clarithromycin,
metronidazole, or omeprazole; previousH. pylori treatment;
or chronic use of nonsteroidal anti-inflammatory drugs (de-
fined as six or more doses per week). Of the 650 enrollees
in the STOMACH study, a convenience sample (patients
who enrolled at times that utility interviewers were avail-
able, n5 73) was invited to participate in utility assessment
interviews.
Utility Elicitation
We selected the time trade-off method for utility elicitation
instead of the standard gamble because the time trade-off is
more comprehensible to many patients (27, 28). Patients
were interviewed by one of two interviewers trained in
utility assessment elicitation techniques. The interviewer
began by presenting the patient with four cards describing
perfect health, mild dyspepsia, moderate dyspepsia, and
severe dyspepsia (see Appendix). Patients were asked which
scenario best described their current health state. Patients
were then provided with an estimate of their remaining life
expectancy based on their current age. They were subse-
quently presented with a visual metric device to facilitate
comparisons of fractional values of remaining life expect-
ancy. The interviewer set the metric to an initial value of
5%, and asked the patient if he/she would prefer to live
his/her entire remaining life expectancy (e.g., 40 yr) with
mild dyspepsia (as described), or 95% of his/her remaining
life (e.g., 38 yr) in “perfect health.” The metric was adjusted
and the question was repeated, until a point of indifference
was determined; this value was recorded as the time trade-
off for mild dyspepsia. This process was repeated for mod-
erate and severe dyspeptic symptoms.
Next, the patients were asked about four ulcer-related
scenarios. Brief descriptions of the symptoms, events, and
procedures involved in having an ulcer-related complication
were given. Patients were then asked how much of their
remaining life expectancy they would trade to avoid the
scenario using a similar technique as described previously.
Patients were also asked to give time trade-off values for a
combination of potential adverse effects of two commonly




Each patient’s time values elicited from the time trade-off
interviews were discounted at a rate of 3% (24). Utility
oefficients for dyspeptic health states were calculated by
dividing each patient’s “perfect health” life expectancy
equivalent by the patient’s estimated life expectancy (29).
The value of health events such as perforation or GI bleed
was determined by calculating the number of QALYs a
patient would exchange to avoid one adverse event. The
median values for the time trade-off utility of the various
levels of dyspepsia as well as the median values of disutility
for ulcer-related complications were used in cost-effective-
ness modeling.
Statistical Analyses
Utilities for mild, moderate and severe dyspepsia were com-
pared using the Mann-Whitney rank sum test for non–
normally distributed data. Cohort-wide estimates for the
time trade-off value of mild, moderate and severe dyspepsia
were compared using the Friedman test for matched groups,
as the data were not normally distributed. The Friedman test
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was also employed to compare the disutilities of ulcer-
related complications. The Bonferroni correction was used
to adjust for the effect of multiple comparisons. Confidence
intervals were estimated using a binomial approximation.
All statistical analyses were performed using Stata 5.0
(Stata, College Station, TX).
Cost-Effectiveness Analyses
Using the MEDLINE database for the years 1966–2000 as
well as reference lists from published articles, we identified
16 candidate economic analyses that examined the cost-
effectiveness of various strategies for treating uninvesti-
gated dyspepsia or peptic ulcer disease. We confined our
search to articles that compared strategies for the treatment
of H. pylori and that produced an explicit cost-effectiveness
ratio or cost-benefit monetary value. As our utility calcula-
tion yielded the QALY value of a clinical event, we further
limited our search to studies that published incremental
cost-effectiveness ratios in terms of cost per ulcer-related
clinical event (Table 1). This criterion eliminated five stud-
ies that stated the costs of treatment in terms of “average
cost per patient” (10, 14, 16, 17, 22) and three studies that
computed empirical cost savings of one strategy compared
with another strategy (12, 19, 20). Finally, three studies
listing effectiveness in terms of “average time without ul-
cer” were also excluded, as our utilities did not measure
disutility from ulcer as time spent in the “ulcer” health state
(2, 8, 18). The five cost-effectiveness analyses we identified
as appropriate for conversion each took a payer perspective
for cost accounting. Finally, we abstracted the “dominant”
(least costly and most effective) strategy from each study
(Table 1).
Conversion of Cost-Effectiveness Ratios
To convert the effectiveness of an “additional ulcer pre-
vented” to QALYs gained we estimated the average disutil-
ity of an ulcer. We assumed that patients who develop an
ulcer have a 5% annual rate of complication (i.e., requiring
hospital admission/invasive procedures) (30, 31). We esti-
mated that 92% of such patients would be admitted with GI
bleeding, 6% would have a perforation, and 2% would die
(31–33). As published data on ulcer complication rates do
not differentiate between index and recurrent ulcers, we
assumed that all ulcers would have the same rate of com-
plications and death. By multiplying these frequencies by
the empirically measured disutilities for each event, an over-
all average disutility in terms of QALYs lost per ulcer was
determined. We then tested our assumptions by performing
sensitivity analyses that varied the rate of ulcer complica-
tion, bleeding, perforation, and death over ranges obtained
from the medical literature.
To approximate the average number of days of dyspeptic
symptoms expected per ulcer occurrence, we used published
data on the health impact of peptic ulcer that measured the
average number of “restricted activity days” (analogous to
our “moderate dyspepsia” category) and “bed days” (similar
to our “severe dyspepsia” category) per year in 4580 pa-
tients with self-reported ulcers (30). This estimated that each
ulcer would cause, on average, 12 days of severe dyspeptic
symptoms and 23 days of moderate symptoms. The total
Table 1. Results of Cost-Effectiveness Analyses Using Empirically-Derived Utility Data
Author (Year)Ref. Population/disease Comparison Primary Result
O’Brien (1995)13 Diagnosed duodenal ulcer Empiric anti-secretory/antimicrobial
therapy compared to no therapy
$383 (Canadian) per recurrent
ulcer prevented
Fendrick (1995)7 Uninvestigated dyspepsia Empiric anti-secretory/antimicrobial
therapy compared to no therapy
$4155 per additional ulcer
cured
Jossson (1996)11 Diagnosed duodenal ulcer Empiric anti-secretory/antimicrobial
therapy compared to no therapy
7420 krona per ulcer relapse
prevented
Ebell (1997)6 Uninvestigated dyspepsia Empiric anti-secretory/antimicrobial
therapy compared to no therapy
$5781 per additional ulcer
cured
Duggan (1998)5 Diagnosed duodenal ulcer Treating patients who test positive
for H. pylori compared to no
therapy
240 pounds per additional
ulcer prevented
2000 Dyspepsia
“Test and Treat” strategy
Uninvestigated dyspepsia Testing forH. pylori and treating if
positive, compared to no therapy
N/A
Author (Year)
Result Converted to Dollar/QALY
Using Time Trade-off Utilities
Range with Varied
Utility Estimates
O’Brien (1995) $3,100/QALY $1,800–$6,900
Fendrick (1995) $45,500/QALY $25,500–$99,400
Jonsson (1996) $12,500/QALY $7,000–$27,300
Ebell (1997) $59,400/QALY $33,200–$129,700
Duggan (1998) $4,700/QALY $1,300–$20,500
2000 Dyspepsia $26,800/QALY $15,000–$58,600
“Test and Treat” strategy
Currency conversion: 1995) 1 Canadian dollar5 $0.75 US; 1996) 1 Swedish krona5 $0.1504 US; 1998) 1 British pound5 $1.631 US (61). All values then normalized to year
2000 $US.
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disutility of an ulcer was therefore the sum of the event-
related disutility (i.e., bleeding, obstruction) plus the dis-
utility of 35 days of dyspeptic symptoms.
To convert “additional cases ofH. pylori eradicated” to
QALYs, we used published estimates of the lifetime inci-
dence of ulcer inH. pylori infected individuals (30, 31),
which suggested that forH. pylori eradication the average
number-needed-to-treat to prevent one clinically apparent
ulcer is 10 (range, five to 20). In converting cost-effective-
ness ratios from published models that used time horizons
.1 yr, we discounted health benefits and costs at 3% an-
nually (5, 11, 24). The rate of ulcer complications was
assumed not to vary over the lifetime of the patient. Non-US
currencies were converted into the appropriate US dollar
amounts using exchange rates appropriate for the year of
publication. All converted costs were inflated to year 2000
dollars using the consumer price index for medical services.
Updated Dyspepsia Analysis
Several investigations since 1997 (the date of the most
recent dyspepsia analysis included in our study) have en-
hanced understanding of ulcer andH. pylori epidemiology,
H. pylori test characteristics, treatment efficacy, and ulcer
recurrence rates (34–41). We updated our dyspepsia treat-
ment model to reflect this new evidence; we also substituted
year 2000 cost data to estimate the current cost-utility ratio
for the management of dyspepsia. Details of the design and
assumptions of this model, which took the “payer perspec-
tive” in measuring healthcare costs, have been published
elsewhere (7). Several recent clinical practice guidelines
have recommendedH. pylori testing rather than empiric
therapy as initial management for dyspepsia (34, 42–45),
reflecting decreases in the cost of initial testing combined
with better estimates ofH. pylori prevalence. Thus, a strat-
egy of “test and treat” was employed for the management of
dyspeptic patients in our updated model, as this strategy was
determined to be the most cost-effective option. Our base-
line assumptions included aH. pylori prevalence of 33%
and an ulcer prevalence of 20% (80% of these ulcers were
ascribed toH. pylori). 14C urea breath testing was used as an
initial screening test in our model, with positive tests result-
ing in treatment withH. pylori eradication therapy. Patients
who tested negative forH. pylori were given an initial trial
of H2-receptor antagonists. Cost estimates included $600
per endoscopy, $150 for urea breath testing, and $25 for
rapid urease testing at endoscopy, $190 forH. pylori erad-
ication therapy, and $45 per month for maintenance antise-
cretory therapy. The cost per ulcer cured was calculated, and
this value was converted to a cost-utility ratio using our
derived QALY value of a prevented ulcer.
RESULTS
The 73 patients with peptic ulcer disease or uninvestigated
dyspepsia included patients with a wide range of symptoms
(Table 2). The proportions of African American, Asian,
Latin American, and Caucasian patients were similar to the
corresponding proportions of adults in northern California
(46). Most patients were taking H2-receptor antagonists
regularly, and some had been taking acid-suppression ther-
apy for up to 8 yr. Fewer than half of the patients had
experienced a complication from a previous ulcer.
Dyspepsia-Related Utilities
Patients with mild and moderate dyspepsia assigned similar
utility scores to their health states. Patients with severe
dyspepsia reported a lower median quality-of-life time
trade-off score (Table 3), although this difference did not
reach statistical significance (p 5 0.06) compared with mild
and moderate dyspeptic patients. Among the entire cohort
the median score for severe dyspepsia (0.87) was signifi-
cantly less than the score for mild or moderate dyspepsia
Table 2. Characteristics of 73 Patients on Chronic Acid-




Average age, yr 576 13 (20–76)
Female sex 43 (59%)
Race
Caucasian 46 (63%)
African American 12 (16%)
Asian 4 (6%)
Latin American 4 (6%)
Other 7 (10%)
Current disease severity*
“Perfect health” 1 (1%)
Mild symptoms 18 (25%)
Moderate symptoms 29 (40%)
Severe symptoms 25 (34%)
History of ulcer-related complications
Obstruction without surgery 7 (10%)
Obstruction with surgery 4 (5%)
Gastrointestinal bleeding 11 (15%)
Perforated ulcer 2 (3%)
None of the above 50 (68%)
Current acid-suppression medication
H2-receptor antagonists† 60 (82%)
Proton-pump inhibitors 15 (21%)
None‡ 1 (1%)
Duration of acid-suppression therapy, yr 3.46 1.3 (1–8)
Highest educational level attained
11th grade or less 4 (5%)
High school graduate or equivalent 14 (19%)
Some college or technical school 35 (48%)
College graduate 15 (21%)
Graduate degree 5 (7%)
Annual household income§




Greater than $80,000 7 (11%)
* Refer to Appendix.
† Three patients reported concurrent H2-receptor antagonist and proton pump
inhibitor use.
‡ One patient reported recent use of H2-receptor antagonists (in past 12 months)
but denied current use.
§ Eleven patients refused to provide annual income information.
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(0.92, p , 0.0001). No significant differences were noted
between the utility scores for mild, moderate, and severe
dyspepsia assigned by patients actually in that particular
health state compared to the utility scores assigned by pa-
tients who were not in the health state. Additionally, no
statistical difference was found between the utility scores
assigned to mild, moderate, and severe dyspepsia when the
respondents were stratified by age or by the presence of a
diagnostically confirmed ulcer (Table 4).
Event-Related Disutilities
The distributions for event-related disutilities were highly
skewed; 32% of the patients indicated that they would be
unwilling to trade any of their remaining life expectancy to
avoid an ulcer-related complication. Among the remaining
patients, the range for disutility of gastric outlet obstruction
was 0.01–3.56 QALYs, for GI bleeding was 0.01–12.41
QALYs, for obstruction requiring surgery was 0.01–17.27
QALYs, and for perforation was 0.01–23.81 QALYs (Table
5). The distributions of these values for all participants and
for the subset who reported nonzero time trade-off values
were significantly different when compared statistically
(p , 0.0001). There was no significant difference noted
between patient preferences for the twoH. pylori antibiotic
courses.
Using these utility data and the assumptions regarding the
frequency of adverse ulcer-related events, we estimated that
an ulcer had a disutility of 0.11 QALY, of which approxi-
mately 0.09 was attributable to dyspeptic symptoms,
whereas 0.02 was lost from complications including death.
These results did not vary when derived only from the
subset of patients with a diagnostically confirmed ulcer or
the subset with uninvestigated dyspepsia. By varying our
assumptions on the epidemiology of ulcer-related compli-
cations and death to the highest estimates published in the
literature combined with using the maximal 95% confidence
boundaries for disutilities, we estimated a maximal disutility
per ulcer of 0.19 QALY. Using the lowest published esti-
mates for the rates of ulcer-related complications combined
with the minimal 95% confidence estimates for adverse-
event and dyspepsia-related disutilties yielded a minimum
estimate for disutility per ulcer of 0.05 QALY.
Application of Utilities to Published
Cost-Effectiveness Analyses
Of the five studies that we examined, three dealt with the
treatment of peptic/duodenal ulcer and two focused on un-
investigated dyspepsia. Using our “base case” estimate of
the disutility of an ulcer, we determined that the initial
treatment of duodenal ulcer patients with empiric antibiotic/
antisecretory therapy had a cost-utility ratio between $3,100
and $12,500 dollars per QALY gained (Table 1). Empiric
treatment of uninvestigated dyspeptic patients withH. pylori
eradication therapy cost between $44,700 and $58,300 per
QALY gained. The range of cost-effectiveness ratios for
peptic ulcer disease management was less than $50,000
through a wide range of varying assumptions, although
dyspepsia treatment exceeded $100,000 per QALY gained
under some conditions (Table 1) (47).















None 73 n/a 1 1 72 n/a
Mild 73 0.92 (0.91–0.96) 18 0.91 (0.89–0.96) 55 0.93 (0.90–0.96)
Moderate 73 0.91 (0.90–0.94) 29 0.90 (0.87–0.96) 44 0.91 (0.89–0.94)
Severe 73 0.87 (0.81–0.90) 25 0.87 (0.79–0.94) 48 0.87 (0.73–0.89)













Youngest (21–47) 18 0.91 (0.89–0.96) 0.92 (0.89–0.97) 0.88 (0.59–0.91)
Second (47–59) 18 0.95 (0.92–0.96) 0.93 (0.89–0.96) 0.90 (0.74–0.94)
Third (59–65) 18 0.95 (0.87–0.96) 0.91 (0.87–0.95) 0.87 (0.79–0.95)
Oldest (.65) 19 0.91 (0.87–0.96) 0.91 (0.87–0.96) 0.78 (0.62–0.88)
p Value for difference between quartiles 0.23 0.54 0.26
Diagnosis upon study entry n
Confirmed ulcer* 10 0.89 (0.81–0.96) 0.93 (0.82–0.96) 0.88 (0.54–0.95)
Uninvestigated dyspepsia 63 0.93 (0.91–0.96) 0.91 (0.90–0.94) 0.87 (0.79–0.91)
p Value for difference between groups 0.21 0.78 0.80
* Confirmed by endoscopy or barium swallow before enrollment in the study.
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Application of Utilities to Updated Dyspepsia Analysis
Using the revised model for the “test and treat” strategy
using 2000 clinical and cost data, we calculated a value of
$2788 per ulcer cured for a strategy of managing uninves-
tigated dyspepsia that used initialH. pylori testing proceed-
ing to eradication therapy if testing was positive. This was
equivalent to a cost-utility ratio of $26,800 per QALY
gained. Sensitivity analysis suggested a “low cost” bound-
ary of $15,000 and a “high cost” boundary of $58,600 per
QALY for this model.
DISCUSSION
Major Findings
Our results suggest that interventions directed atH. pylori
are cost-effective in patients with peptic ulcer disease and
potentially cost-effective in those with uninvestigated dys-
pepsia, compared with other medical interventions (Table
6). Time trade-off utilities for dyspeptic symptom health
states and ulcer-related health events were easily measured
and were ordered by degree of severity, raising confidence
that patients can provide valid measures of utilities. Based
on the utilities of the patients we interviewed,.80% of the
value of ulcer prevention can be attributed to symptom
reduction; the remainder can be ascribed to reducing the risk
of death or ulcer-related complications such as perforation
or bleeding.
Comparisons With Other Studies
Previous studies of health-related quality of life for patients
with dyspepsia, peptic ulcer, or gastroesophageal reflux
disease have used rating-scale instruments such as the GI
Symptom Rating Scale. Such indices have been more thor-
oughly evaluated than utility assessment in patients with
upper GI syndromes (48–50), but they cannot be reliably
converted into quality-adjusted life years (28, 51–54). Util-
ities are uniquely useful because they enable health benefits
to be measured in QALYs, which allow comparisons with
other health care interventions.
We elicited utilities in patient interviews using the widely
accepted time trade-off method (28). Only one prior analysis
of the cost-effectiveness of treating dyspeptic patients has
used QALYs. Ebellet al. designed a Markov model com-
paring seven different strategies for empiric management of
dyspeptic patients (6). Utility measurements were estimated
from Index of Well-Being scores. Ebellet al. assumed the
disutility of inpatient treatment of a complicated ulcer was
0.021, which is similar to the values we obtained from
empiric measurements. However, the model of Ebellet al.
did not incorporate dyspepsia-related disutility, which was
the largest component of overall ulcer-related disutility in
our study.
Not surprisingly, our findings confirm the cost-effective-
ness of empiric treatment ofH. pylori at the time of initial
diagnosis of duodenal ulcer (5, 11, 13). Incorporating our
study’s empiric utilities in the analyses of Ebellt al. and
Fendricket al. (6, 7) suggests that strategies focused on the
early treatment ofH. pylori in the management of uninves-
tigated dyspepsia are possibly cost-effective, but less so than
the eradication ofH. pylori in peptic ulcer disease. This is
due toH. pylori eradication being far more effective in the
treatment of duodenal ulcer disease (80–90% cure rate with
radication therapy at 1 yr) (55, 56) compared with nonulcer
yspepsia (0–22% cure rate with eradication therapy at 1 yr)
(37, 57, 58). Indeed, it is possible that the only dyspeptic
patients who benefit fromH. pylori eradication are those
with actual ulcers causing their dyspepsia.
The question of whetherH. pylori eradication is an ef-
fective component of managing uninvestigated dyspepsia is





Obstruction without operation 0 (0–0.01) 0–3.6
Gastrointestinal bleed 0.01 (0–0.01) 0–12.4
Obstruction with operation 0.01 (0–0.05) 0–17.3








Table 6. Comparison of Cost Per QALY Values of Common Medical Interventions
Intervention Reference Case Cost/Utility Ratio
Instituting dialysis and continuing aggressive therapy in hospitalized adults with very
poor prognoses
$298,200/QALY62
Endoscopic surveillance every 5 yr in patients with Barrett’s esophagusversusno
surveillance
$99,900/QALY63
Allogenic bone marrow transplant for a 35-yr-old woman with chronic myelogenous
leukemiaversusinterferon
$54,600/QALY64
Proton-pump inhibitors as first line therapy for patients with mild gastroesophageal
reflux disease
$37,900/QALY65
Primary angioplasty for acute myocardial infarction compared with thrombolysis $13,100/QALY66
Hip replacement for men with osteoarthritis aged 85 yr compared to no therapy $5,100/QALY67
Interferona-2B plus ribavirin for hepatitis Cversusno therapy Cost saving68
Values inflated to year 2000 dollars from publication year using the consumer price index for medical services.
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highly controversial (59). Understanding the relative eco-
nomic value ofH. pylori treatment for uninvestigated dys-
pepsia can lend insight into difficult decisions about appro-
priate management strategies. Of note, our Markov model
indicated that dyspepsia management using a “test-and-
treat” initial strategy was more cost-effective than the op-
timal management strategies published in previous eco-
nomic studies of uninvestigated dyspepsia. Sensitivity
analysis of our model suggested an upper cost per QALY
boundary of $57,500, which is comparable to other inter-
ventions deemed cost-effective in the United States (47, 60).
Limitations
Our analysis has important limitations. First, the average
number of symptomatic days per ulcer was extrapolated
from population data; the actual value is unknown. Our
estimates could result in inappropriately high or low esti-
mates for the QALY value of an ulcer. We addressed this by
varying the inputs used in calculating the disutility of an
ulcer in our sensitivity analyses to provide a reasonable
estimate of the range of possible values.
Second, the ideal method of incorporating empirically
measured utilities is in the design and execution of an
analytic model; this was not feasible for any of the published
analyses we examined. It is possible that converting the end
product of an analysis (i.e., dollars per cured ulcer into
dollars per QALY) may inadvertently omit some of the
nuances of cost and effectiveness accounting that complex
models are designed to capture.
Third, our study population may have not adequately
represented “typical” patients with ulcer disease or uninves-
tigated dyspepsia who were the subjects of the published
cost-effectiveness models. As our study comprised patients
with chronic, refractory symptoms, it is possible that our
patients experienced greater disutility from their symptoms
and had greater concern about ulcer-related complications.
We may therefore have overestimated the cost-effectiveness
of uninvestigated dyspepsia and ulcer management. How-
ever, we found that our patients’ assessments of the utility
of mild, moderate, and severe dyspepsia were independent
of current symptom level. Additionally, some cost-effec-
tiveness analysts have argued that patients who are actually
in “poor” health rate their quality of life as higher than do
healthier patients asked to estimate the quality of their life if
they were in “poor” health (60), thus utility ratings in our
patients may have been higher than in typical patients with
episodic dyspepsia or peptic ulcer. We may therefore have
underestimated the cost-effectiveness of dyspepsia and ulcer
management, inasmuch as patients with symptoms that are
less chronic or refractory may perceive greater disutility
from their symptoms and thus stand to gain greater benefits
from treatment (60). Further investigation of the utility of
dyspepsia in different populations is needed to address these
issues.
Finally, patients with actual ulcers may experience dis-
utility from their symptoms different from that of patients
with other diagnoses (e.g., nonulcer dyspepsia). Never-
theless, our study detected no difference in utility scores
between patients with confirmed ulcers and those with
uninvestigated dyspepsia, suggesting any variation in
symptom-related disutility among dyspeptic patients with
differing diagnoses is small.
In conclusion, our analysis indicates that patients with
peptic ulcer disease and ulcer-like dyspepsia assign their
health states substantial disutility. Expressing the cost-ef-
fectiveness of interventions for these conditions in dollars
per QALY captures their value in improving health-related
quality of life and highlights opportunities for clinical care
to prevent lost quality of life. Cost per QALY ratios also
provide a way to directly compare ulcer and uninvestigated
yspepsia intervention cost-effectiveness with other health-
care interventions. The eradication ofH. pylori is relatively
cost-effective for patients with peptic ulcer disease; how-
ever, the cost-effectiveness ofH. pylori eradication as an
initial step in the management of all dyspeptic patients is
less certain. Further economic, clinical, and epidemiological
studies are necessary to ascertain better the cost-effective-
ness of earlyH. pylori eradication in these patients.
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APPENDIX. HEALTH STATE DESCRIPTIONS
Perfect Health
● No abdominal symptoms
● No need for medications
● No need for avoiding certain foods/drinks
● No sleep distrubances from abdominal symptoms
● No anxiety about gastrointestinal disease
Mild Symptoms
● Abdominal symptoms 2–3 times a week or less
● Symptoms resolve quickly by taking medication
● Do not have to avoid specific drinks or foods
● Rarely wake up during the night
● Rarely feel anxious
Moderate Symptoms
● Abdominal symptoms about once a day
● Not always resolved by medication
● May have to avoid drinks with caffeine, alcohol,
aspirin, and/or other pain relievers
● Wake up during the night about once a week
● Often feel anxious
Severe Symptoms
● Have abdominal symptoms more than once a day
● Take medication daily
● Consistently have to avoid specific drinks, foods, and/or
medications
● Wake up during the night at least 2–3 time a week
● Almost always feel anxious
Adverse Effects of Omeprazole/
Amoxicillin/Clarithromycin
● Mild nausea or diarrhea for 10 days
● Headache
● Funny taste in mouth
● Abdominal pain
Gastrointestinal Bleeding
● Vomiting blood prompts emergency room visit
● Blood transfusion and endoscopy performed*
● Two days in intensive care unit
● Nasogastric tube for 2 days*
● Three days in regular hospital bed with restricted diet
● Daily medication for at least 2 months
Obstruction—No Operation
● Problems with eating for a few weeks, causing nausea,
vomiting, pain, and bloating
● Endoscopy*
● Nasogastric tube for 2 days*
● Three days in regular hospital bed with restricted diet
● Daily medication for at least 2 months
Obstruction—With Operation
● Problems with eating for a few weeks; nausea, vomiting,
pain, and bloating
● Endoscopy*
● Major operation on stomach; postoperative pain after-
ward*
● Nasogastric tube for 7 days*
● Seven days in regular hospital bed with restricted diet
● Daily medication for at least 2 months
Perforation
● Sudden, severe abdominal pain, nausea, bloating prompts
emergency room visit
● Major operation on stomach; postoperative pain after-
ward*
● Nasogastric tube for 7 days*
● Seven days in regular hospital bed with restricted diet
● Daily medication for at least 2 months
Adverse Effects of Omeprazole
Metronidazole/Clarithromycin
● Must avoid alcohol for 14 days
● Moderate nausea
● Abdominal pain
● Funny taste in mouth
*Endoscopy, blood transfusion, nasogastric tube, and surgery were explained in extended detail.
347AJG – February, 2001 H. pylori Eradication and Quality of Life
